PHILADELPHIA, June  10, 2026  (GLOBE NEWSWIRE) -- On June 4, 2026, Barrack Rodos &amp; Bacine filed a class action lawsuit seeking to represent purchasers of GeneDx Holdings Corp. (NASDAQ:WGS) common stock between April

Investor Notice of Barrack, Rodos & Bacine Concerning Its Lawsuit Against GeneDx Holdings Corp. (WGS)

GeneDx faces securities class action over Fabric Genomics impairment

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>PHILADELPHIA, June  10, 2026  (GLOBE NEWSWIRE) -- On June 4, 2026, Barrack Rodos &amp;amp; Bacine filed a class action lawsuit seeking to represent purchasers of GeneDx Holdings Corp. (NASDAQ:WGS) common stock between April</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>Barrack, Rodos &amp; Bacine filed a securities class action against GeneDx (WGS) alleging misstatements related to Fabric Genomics viability. The May 4, 2026 results showed a large operational loss, margin compression, and a $31.3 million impairment tied to Fabric Genomics, triggering a 49% stock decline. The suit adds litigation risk and may pressure earnings resilience and capital allocation decisions.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>Barrack, Rodos &amp; Bacine filed GeneDx class-action alleging SEC violations.</li><li>Class period Apr 16, 2025–May 4, 2026; alleges Fabric Genomics viability issues.</li><li>May 4, 2026 results: $57.5m loss, -$0.28 EPS, 69% gross margin; $31.3m impairment.</li><li>Stock fell ~49% after results; about $33.42 drop.</li><li>Lead plaintiff motions due by Aug 3, 2026.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>GeneDx Holdings Corp (WGS)</strong>: Subject of securities class action; litigation risk and impairment disclosures.</li><li><strong>Fabric Genomics (N/A)</strong>: Acquired by GeneDx; impairment cited; viability issues highlighted in suit.</li><li><strong>Barrack, Rodos &amp; Bacine (N/A)</strong>: Plaintiff law firm; not a market-focused company, but driving litigation narrative.</li></ul>
  </section>

  <section data-block="category">
    <h3>Legal</h3>
    <p>Category: Legal. This is a securities-litigations catalyst tied to GeneDx’s Fabric Genomics deal; potential impact on valuation through legal risk and impairment exposure.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>Legal action could heighten regulatory scrutiny and potential liability costs.</li><li>Fabric Genomics impairment ties to the acquisition may pressure profitability.</li><li>May 4, 2026 earnings miss and margin compression drove a large stock drop.</li><li>Lead plaintiff deadline August 3, 2026 could amplify near-term volatility.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>Class Period: Apr 16, 2025–May 4, 2026.</li><li>May 4, 2026: operating loss $57.5m; EPS -$0.28; gross margin 69%.</li><li>$31.3m impairment attributed to Fabric Genomics.</li><li>Earnings guidance cut from $540–$555m to $475–$490m.</li><li>Stock declined 49% (~$33.42) on the news.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>Bearish in the near term (1–3 quarters) due to ongoing litigation risk and impairment exposure.</p>
  </section>
</section>


<link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css"></link><p>PHILADELPHIA, June  10, 2026  (GLOBE NEWSWIRE) -- On June 4, 2026, Barrack Rodos &amp; Bacine filed a class action lawsuit seeking to represent purchasers of GeneDx Holdings Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/WGS">WGS</a>) common stock between April 16, 2025 and May 4, 2026, inclusive (the "Class Period").  Captioned Basma v. GeneDx Holdings Corp., No. 26-cv-00880 (D. Conn.), the lawsuit charges GeneDx and certain of its top executive officers with violations of the Securities Exchange Act of 1934.</p>  <p><strong><em>If you purchased GeneDx stock during the Class Period, suffered substantial losses, and wish to serve as lead plaintiff of the GeneDx class action lawsuit, please contact the firm by calling Linda Border or Mark Stein at 877-386-3304, or via email at</em></strong> <a href="https://www.globenewswire.com/Tracker?data=rVZGkCpdut5IjLQvvLLNsw037LBxOI2NYcaN2HnulucsFgHkchzPSIj7MVvnQAlGd-CEXPfN5Mj2vHPfDb1er7FRuFlAhiv6tk1KETjmI3yXygLyoFJL9Fs32vGlG1dM" rel="nofollow" target="_blank">investoralert@barrack.com</a>, <strong><em>or by visiting the firm's web site by clicking </em></strong><a href="https://www.globenewswire.com/Tracker?data=SKmJx_YMiIT3nUGwn-hd8LUPT86o-VglEE2c-0E-0996VaDmlsa7XK35YIe5xf4QAPrXNJqbz64Y_Bk4kUi-r5hLS1yHbFFPrSCZwlQ5ACKBC63CrZTy3-1BuNksn7YM" rel="nofollow" target="_blank"><strong><em>here</em></strong></a>.  <strong><em>Lead plaintiff motions for the GeneDx class action lawsuit must be filed with the court no later than August 3, 2026.</em></strong></p>  <p><strong>WHAT'S THIS ABOUT?</strong></p>  <p>GeneDx is a genomics company that provides genetic testing services.  On April 16, 2025, GeneDx announced an agreement to acquire Fabric Genomics, a company focused on AI-driven genomic interpretation.</p>  <p>The lawsuit filed by Barrack, Rodos &amp; Bacine alleges that defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose significant problems in Fabric Genomic's viability that would negatively impact GeneDx's overall business and operations.</p>  <p>On May 4, 2026, GeneDx announced its 2026 first quarter results, revealing a loss in operations of $57.5 million and earnings per share of -$0.28, a drop in adjusted gross margin from 74% to 69%, and a $31.3 million impairment loss directly attributable to Fabric Genomics.  GeneDx also reduced its projected earnings from $540-$555 million to $475-$490 million.  On this news, GeneDx's share price fell over 49%, or $33.42 per share, from the close on the previous day.</p>  <p><strong>THE LEAD PLAINTIFF PROCESS</strong>:</p>  <p>The Private Securities Litigation Reform Act of 1995 permits any investor who purchased GeneDx common stock during the Class Period to seek appointment as lead plaintiff in the GeneDx class action lawsuit.  A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class.  A lead plaintiff acts on behalf of all other class members in directing the GeneDx class action lawsuit.  The lead plaintiff can select a law firm of its choice to litigate the GeneDx class action lawsuit.  An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the GeneDx class action lawsuit.</p>  <p><strong>WHO WE ARE:</strong></p>  <p>Having been founded in 1976, Barrack, Rodos &amp; Bacine has fifty years of experience prosecuting securities law class actions, including cases involving accounting fraud and insider trading.  The Firm has achieved some of the largest recoveries in U.S. history for securities litigation, including a $6.19 billion recovery for WorldCom investors, $3.32 billion for Cendant investors, $1.05 billion for McKesson investors, and $970.5 million for AIG investors.</p> <img alt="" class="__GNW8366DE3E__IMG" src="https://www.globenewswire.com/newsroom/ti?nf=OTczNTA3NiM3NjU2MTAxIzIwMjQ3NTc="></img> <br></br><img alt="" src="https://ml.globenewswire.com/media/ZDMyYjc3MWYtNjgwNC00YjJlLTljN2QtZjI4NTM0YTc2ZjEyLTEwMzYzMjktMjAyNi0wNi0xMC1lbg==/tiny/Barrack-Rodos-Bacine.png" referrerpolicy="no-referrer-when-downgrade"></img>

Barrack, Rodos & Bacine filed a securities class action against GeneDx (WGS) alleging misstatements related to Fabric Genomics viability. The May 4, 2026 results showed a large operational loss, margin compression, and a $31.3 million impairment tied to Fabric Genomics, triggering a 49% stock decline. The suit adds litigation risk and may pressure earnings resilience and capital allocation decisions.

Investor Notice of Barrack, Rodos & Bacine Concerning Its Lawsuit Against GeneDx Holdings Corp. (WGS)

AI Summary

Sentiment Rationale

Trading Thesis

Market-Moving

Key Facts

Companies Mentioned

Legal

Related News